Caris Life Sciences, Inc. (CAI) SEC Filings & Earnings Calls

Net loss still present, though significantly reduced.

“Net loss was $0.6 million for the three months ended June 30, 2026.” · word for word

Customer concentration

“Payer 1 37.3% 44.7% 38.6% 47.3% 23.5% 18.4%” · word for word

DOJ investigation

“In March 2025, the Company received a Civil Investigative Demand (“CID”) from the U.S. Department of Justice in connection with an investigation under the False Claims Act (“FCA”) regarding the Company’s compliance with Medicare’s date of service rule” · word for word

Material weakness in internal controls

“our principal executive officer and principal financial officer have concluded that these disclosure controls and procedures were not effective at the reasonable assurance level as of June 30, 2026 due to the previously reported material weakness in our internal control over financial reporting”

Reimbursement Concentration Risk

“Revenue from clinical cases for patients covered by Medicare represented approximately 41.2% and 54.3% of our molecular profiling services revenue for the three months ended March 31, 2026 and 2025, respectively.” · word for word

Near-Term Net Loss Risk

“While we have achieved net profit for the three months ended September 30, 2025 and December 31, 2025, we may continue to incur net losses in the near future.” · word for word

Scaling Infrastructure Risk

“Revenue may be impacted in the event that we are not able to meet the increase in demand.” · word for word

Net loss persists despite improvement; reliance on continued volume growth and ASP improvements for profitability.

“Net loss of $0.5 million, though significantly improved from $102.6 million loss in prior year.”

Operating expenses growing 18% YoY, driven by stock-based compensation and headcount, could pressure margins if revenue growth slows.

“Operating expenses were $136.1 million...increase of $21.1 million, or 18%.”

CEO Dominance Risk

“David Dean Halbert serves as both our Chief Executive Officer and as Chairman of our Board of Directors.” · word for word

Related Party Transaction Risk

“We lease approximately 30,500 square feet of office space in Irving, Texas for our principal executive offices pursuant to a lease expiring in April 2028. Our complete and timely performance of each obligation under the lease agreement is unconditionally and irrevocably guaranteed by David Dean Halbert, our Founder, Chairman and Chief Executive Officer, and ” · word for word

High leverage with $400M term loan; covenants include minimum $50M cash; interest rate SOFR+5%.

“Interest rates... Term SOFR Rate plus 5.00%; minimum qualified cash of $50 million”

Revenue concentration risk

“MI Profile accounted for 84.4% of revenue; any decline in adoption would materially impact results.”

Reimbursement risk

“PAMA will reduce Medicare CLFS rates by up to 15% per year from 2027-2029, impacting key solutions.”

Profitability risk

“Accumulated deficit of $2.5B and net loss of $68.1M in FY2025; company may not achieve profitability.”

Regulatory compliance risk

“FDA enforcement powers could result in product restrictions, recalls, or withdrawal of approvals.”

Dependence on successful launch of Caris Detect MCED test; regulatory and reimbursement risks.

“Interim readout of Achieve 1 study supporting upcoming launch of Caris Detect, multi-cancer early detection test.”

Preliminary results subject to change; audit not complete

“Preliminary unaudited results; company warns final results may differ”

Reimbursement concentration and PAMA risk

“For many tests and/or laboratories, the result of the PAMA pricing methodology has been lower pricing and reimbursement.” · word for word

Dependence on single product (MI Profile)

“MI Profile... accounted for 93.34%... of our revenue for the nine months ended September 30, 2025”

Significant accumulated deficit and ongoing losses

“As of September 30, 2025, we had an accumulated deficit of $2.6 billion.” · word for word

High debt and interest expense

“As of September 30, 2025, we had $400.0 million of borrowings outstanding under the 2023 Term Loan Agreement... the interest rate was 10.8%.” · word for word

Regulatory uncertainty for LDTs and FDA post-approval conditions

“The regulation of LDT products in the United States remains subject to significant uncertainty” · word for word